This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Oct 2012

LEO Pharma receives FDA approval for Taclonex

Taclonex has been approved by the US Food and Drug Administration for first-line treatment of scalp and body plaque psoriasis.


Leo Pharma has announced the receipt of approval from the US Food and Drug Administration for Taclonex (a combination of calcipotriene and betamethasone diproprionate) Topical Suspension.

Related News